{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epithelial+Neoplasms%2C+Malignant&page=3", "query": { "condition": "Epithelial Neoplasms, Malignant", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 14689, "total_pages": 1469, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epithelial+Neoplasms%2C+Malignant&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epithelial+Neoplasms%2C+Malignant&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T16:52:36.717Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT07789119", "title": "Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "biospecimen Collection", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50000, "start_date": "2026-09-10", "completion_date": "2038-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07789119" }, { "nct_id": "NCT00309907", "title": "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Juvenile Myelomonocytic Leukemia", "Previously Treated Childhood Rhabdomyosarcoma", "Previously Treated Myelodysplastic Syndromes", "Pulmonary Complications", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "etanercept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 39, "start_date": "2006-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Arcadia", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309907" }, { "nct_id": "NCT05798507", "title": "Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Avutometinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Defactinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 14, "start_date": "2023-07-28", "completion_date": "2027-12-03", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798507" }, { "nct_id": "NCT01625936", "title": "CRLX101 Plus Bevacizumab in Advanced RCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "CRLX101 (Cerulean)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-06", "completion_date": "2018-07-16", "has_results": false, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625936" }, { "nct_id": "NCT03737695", "title": "Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Metastatic Breast Carcinoma", "Peritoneal Effusion", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-09-16", "completion_date": "2027-09-15", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 14, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737695" }, { "nct_id": "NCT03071757", "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-03-21", "completion_date": "2022-04-13", "has_results": false, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 10, "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071757" }, { "nct_id": "NCT07431281", "title": "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "Sonesitatug vedotin", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Zolbetuximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2130, "start_date": "2026-02-03", "completion_date": "2031-10-27", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 80 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07431281" }, { "nct_id": "NCT01040000", "title": "QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "NPC-1C/NEO-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Precision Biologics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 94, "start_date": "2012-01", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-08-04", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040000" }, { "nct_id": "NCT05812807", "title": "Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1295, "start_date": "2023-06-14", "completion_date": "2033-05-31", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-05T16:52:36.717Z", "location_count": 828, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05812807" } ] }